Compare · CI vs MGEN
CI vs MGEN
Side-by-side comparison of The Cigna Group (CI) and Miragen Therapeutics, Inc. (MGEN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CI and MGEN operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI carries a market cap of $77.37B.
- CI has hit the wire 14 times in the past 4 weeks while MGEN has been quiet.
- CI has more recent analyst coverage (25 ratings vs 0 for MGEN).
- Company
- The Cigna Group
- Miragen Therapeutics, Inc.
- Price
- $275.55-1.49%
- -
- Market cap
- $77.37B
- -
- 1M return
- +1.90%
- -
- 1Y return
- -17.71%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 14
- 0
- Recent ratings
- 25
- 0
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Latest CI
- Director Foss Eric J was granted 782 shares, increasing direct ownership by 2% to 36,696 units (SEC Form 4)
- Director Mcclellan Mark B. was granted 782 shares, increasing direct ownership by 13% to 6,891 units (SEC Form 4)
- Director Zarcone Donna F was granted 782 shares, increasing direct ownership by 3% to 27,517 units (SEC Form 4)
- Director Hathi Neesha was granted 782 shares, increasing direct ownership by 23% to 4,151 units (SEC Form 4)
- Director Mazzarella Kathleen M was granted 782 shares, increasing direct ownership by 13% to 6,891 units (SEC Form 4)
- Director Kurian George was granted 782 shares, increasing direct ownership by 21% to 4,560 units (SEC Form 4)
- Director Ross Kimberly A. was granted 782 shares, increasing direct ownership by 17% to 5,294 units (SEC Form 4)
- Director Hennigan Michael J was granted 782 shares, increasing direct ownership by 138% to 1,350 units (SEC Form 4)
- Director Ozuah Philip was granted 782 shares, increasing direct ownership by 43% to 2,583 units (SEC Form 4)
- Director Wiseman Eric C was granted 782 shares, increasing direct ownership by 3% to 23,940 units (SEC Form 4)
Latest MGEN
- SEC Form SC 13G/A filed by Miragen Therapeutics, Inc.
- SEC Form SC 13G filed
- SEC Form SC 13G filed
- SEC Form SC 13G/A filed
- SEC Form SC 13G/A filed
- SEC Form 4 filed by L Joseph Turner
- SEC Form 4 filed by Evan Peter Harwin
- SEC Form 4 filed by S. Jeffrey Hatfield
- SEC Form 4 filed by Tomas Kiselak
- SEC Form 4 filed by Arlene Morris